BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26037683)

  • 1. [Atypical metastatic breast localization in lung cancer].
    Serraille A; Barazzutti H; Greillier L; Barlesi F
    Rev Mal Respir; 2015 Nov; 32(9):953-5. PubMed ID: 26037683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report.
    Alì G; Proietti A; Niccoli C; Pelliccioni S; Borrelli N; Giannini R; Lupi C; Valetto A; Bertini V; Lucchi M; Mussi A; Fontanini G
    Lung Cancer; 2013 Aug; 81(2):297-301. PubMed ID: 23664446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK rearrangement in lung adenocarcinoma with concurrent cervix and breast metastases: A case report.
    Chuang X; Chen Y; Yu P; Qiu X; Wang J; Qu X; Teng Y; Liu Y; Jin B
    Thorac Cancer; 2018 Nov; 9(11):1513-1518. PubMed ID: 30144282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma.
    Wang Q; Yang X; He Y; Ma Q; Lin L; Fu P; Xiao H
    J Mol Diagn; 2015 Sep; 17(5):515-20. PubMed ID: 26142544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Breast metastases from lung cancers with the EGFR mutation].
    Assouline P; Léger-Ravet MB; Saffroy R; Hamelin J; Bénissad A; Husleag P; Lemoine A; Oliviéro G
    Rev Mal Respir; 2017 Jan; 34(1):61-65. PubMed ID: 27282326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of lung adenocarcinoma after an interval of 15 years revealed by demonstration of the same type of EML4-ALK fusion gene.
    Tsukamoto Y; Kanamori K; Watanabe T; Mikami K; Ieki R; Nakano T; Kajimoto K; Hirota S
    Pathol Res Pract; 2014 Dec; 210(12):1112-6. PubMed ID: 25238939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
    Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
    Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
    Pekar-Zlotin M; Hirsch FR; Soussan-Gutman L; Ilouze M; Dvir A; Boyle T; Wynes M; Miller VA; Lipson D; Palmer GA; Ali SM; Dekel S; Brenner R; Bunn PA; Peled N
    Oncologist; 2015 Mar; 20(3):316-22. PubMed ID: 25721120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Inflammatory myofibroblastic tumour'-like dedifferentiation of anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
    Mason EF; Fletcher CD; Sholl LM
    Histopathology; 2016 Sep; 69(3):510-5. PubMed ID: 26880345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
    To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
    J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report.
    Volckmar AL; Endris V; Bozorgmehr F; Lier C; Porcel C; Kirchner M; Leichsenring J; Penzel R; Thomas M; Schirmacher P; Warth A; Stenzinger A
    Diagn Pathol; 2016 Nov; 11(1):133. PubMed ID: 27863497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
    Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
    Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Anai S; Takeshita M; Ando N; Ikematsu Y; Mishima S; Ishida K; Inoue K
    J Thorac Oncol; 2016 Oct; 11(10):e126-8. PubMed ID: 27663401
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.